No. 24-5593

Otis Brandon v. Janssen Pharmaceuticals, et al.

Lower Court: Fourth Circuit
Docketed: 2024-09-20
Status: Denied
Type: IFP
IFP
Tags: drug-labeling fda-citations judicial-review medical-liability mental-capacity pharmaceutical-misconduct
Key Terms:
AdministrativeLaw Environmental SocialSecurity Securities Immigration
Latest Conference: 2024-11-15
Question Presented (AI Summary)

Did the lower courts fail to properly consider evidence of pharmaceutical misconduct and misrepresentation in cases against Janssen and Johnson & Johnson?

Question Presented (OCR Extract)

QUESTION(S) PRESENTED ; 1) Did the lower courts fail to consider.numerous cases alleged agianst the parmaceutical company Janssen and Johnson & Johnson for misrepresentation, falsifying labels, etc? 2) Did the lower: courts fail to consider the numerous cases were the Federal Drug Administration cited the company Janssen Pharmaceuticals and Johnson & Johnson for failure to inform of the dangerous side effects of thier drug? 3) Did the lower courts follow a misinterpretation cf judgement : passed by other Justices and other courts? " 4) Did the lower courts fail to include in their decision same . / similar issues decided in other cases? (see related cases) 5) Did the lower court follow a error of fact? 6) Didi the lower courts fail to take into account numerous . case were ruled against the defendants for allegations sighted , by plaintiff? , 7) Did the lower courts fail to take into account the plaintiffs "lack of Capacity" and Serious Mental Illness?

Docket Entries

2024-11-18
Petition DENIED. Justice Alito took no part in the consideration or decision of this petition.
2024-10-31
DISTRIBUTED for Conference of 11/15/2024.
2024-07-11
Petition for a writ of certiorari and motion for leave to proceed in forma pauperis filed. (Response due October 21, 2024)

Attorneys

Otis Brandon
Otis Brandon — Petitioner
Otis Brandon — Petitioner